

Resource Summary Report

Generated by NIF on Jul 31, 2026

Brilliant Violet 605(TM) anti-mouse Ly-6C

RRID:AB_2562352

Type: Antibody

Proper Citation

BioLegend Cat# 128035, RRID:AB_2562352

Antibody Information

URL: http://antibodyregistry.org/AB_2562352

Proper Citation: BioLegend Cat# 128035, RRID:AB_2562352

Target Antigen: Ly-6C

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-mouse Ly-6C

Description: This monoclonal targets Ly-6C

Target Organism: mouse

Clone ID: Clone HK1.4

Antibody ID: AB_2562352

Vendor: BioLegend

Catalog Number: 128035

Alternative Catalog Numbers: 128036

Record Creation Time: 20250819T235336+0000

Record Last Update: 20250820T064444+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-mouse Ly-6C.

No alerts have been found for Brilliant Violet 605(TM) anti-mouse Ly-6C.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 37 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Sheban F, et al. (2025) ZEB2 is a master switch controlling the tumor-associated macrophage program. *Cancer cell*, 43(7), 1227.

Wang Q, et al. (2025) ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy. *Cell reports*, 44(10), 116314.

Cao Z, et al. (2025) Interferon- γ -stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer. *Cell reports. Medicine*, 6(3), 102017.

Duval F, et al. (2025) Trajectories of macrophage ontogeny and reprogramming in cancer. *iScience*, 28(5), 112498.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Zhang M, et al. (2025) Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy. *Cell host & microbe*, 33(6), 915.

Chaudhry H, et al. (2025) Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitors reduce vascular inflammation in vitro and in vivo. *British journal of pharmacology*.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8⁺ T cell responses and promotes antitumor T cell therapy. *Cell reports*, 43(2), 113712.

Hayes BH, et al. (2024) Chromosomal instability induced in cancer can enhance macrophage-initiated immune responses that include anti-tumor IgG. *eLife*, 12.

Folkert IW, et al. (2024) An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis. *The Journal of experimental medicine*, 221(10).

Ikeda N, et al. (2023) The early neutrophil-committed progenitors aberrantly differentiate into immunoregulatory monocytes during emergency myelopoiesis. *Cell reports*, 42(3), 112165.

Vennin C, et al. (2023) Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity. *Cancer cell*, 41(6), 1170.

Salzmann M, et al. (2023) Staphylococcus aureus extracellular adherence protein (Eap) reduces immune cell phenotype in developing but not in established atherosclerotic lesions. *Biochimica et biophysica acta. Molecular basis of disease*, 1869(3), 166616.

Weckel A, et al. (2023) Long-term tolerance to skin commensals is established neonatally through a specialized dendritic cell subgroup. *Immunity*, 56(6), 1239.

Kolabas ZI, et al. (2023) Distinct molecular profiles of skull bone marrow in health and neurological disorders. *Cell*, 186(17), 3706.

Miranda K, et al. (2022) Yin and yang of cannabinoid CB1 receptor: CB1 deletion in immune cells causes exacerbation while deletion in non-immune cells attenuates obesity. *iScience*, 25(9), 104994.

Eisenstein A, et al. (2022) Activation of the transcription factor NRF2 mediates the anti-inflammatory properties of a subset of over-the-counter and prescription NSAIDs. *Immunity*, 55(6), 1082.

Yang C, et al. (2022) Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity. *Immunity*, 55(7), 1268.

Uceda-Castro R, et al. (2022) Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis. *Cell reports. Medicine*, 3(11), 100821.

Lopez J, et al. (2022) A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4+ T cell immunity. *Cell reports*, 40(4), 111142.